Trial Profile
Phase I/II trial of subcutaneous decitabine maximizing genomic demethylation in patients with myelodysplastic syndrome
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Decitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Eisai Co Ltd
- 01 May 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
- 27 Nov 2006 New trial record.